AstraZeneca Gains Approval for Calquence in Treating Mantle Cell Lymphoma
AstraZeneca Pharma India Limited has received significant regulatory permission for the continued sale and distribution of a key oncology drug. The company confirmed that it obtained clearance from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India, for an additional indication of its product.The approval covers Acalabrutinib maleate tablets 100 mg, which is marketed under the brand name Calquence ®. This development significantly expands the therapeutic scope of the medicine within India.New Indication for Mantle Cell Lymphoma
The new indication allows for the use of Acalabrutinib in combination with...